Open Access401.2: Inhibition of Proprotein Convertase Subtilisin/Kexin Type A (PCSK-9) Among Renal Transplant Recipients: Is It Beneficial For Cases With High Cardiovascular Risk?
Author(s) -
Torki Al-Otaibi,
Osama Gheith,
Ayman Maher Nagib,
Hasaneen Aboatya,
M.A. Halim,
Tarek Said,
Mohamed Emam,
Zakaria El-sayed,
Prasad Nair
Publication year - 2022
Publication title -
transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.45
H-Index - 204
eISSN - 1534-6080
pISSN - 0041-1337
DOI - 10.1097/01.tp.0000887452.97282.90
Subject(s) - medicine , evolocumab , immunosuppression , gastroenterology , kidney transplantation , renal function , pcsk9 , transplantation , urology , cholesterol , lipoprotein , ldl receptor , apolipoprotein a1